SKP | Business Alerts
8 January 2015 | Volume 6 Issue 8
Carve out for medical devices from the Pharma sector, permitting FDI up to 100%

The Department of Industrial Policy & Promotion (DIPP) issued a
press note on 6 January 2014. The note announced that the medical devices industry has been carved out from the pharmaceutical sector and that FDI in this segment will now follow the automatic route. Previously, the medical devices sector was under the pharmaceutical category where FDI up to 100% was permitted subject to certain conditions (viz. non-compete clause).  On 24 December 2014, the Union Cabinet had approved the amendment of the existing FDI norms to allow 100% FDI in medical devices through the automatic route. This new development comes as a major relief for the cash-starved medical devices sector.

India has achieved an eminent global position in the Pharma sector.  But the same cannot be said about the medical devices industry.  The medical devices industry is highly dependent on imports with over 70% of the demand being satisfied by such imports. Low or no custom duty also aided imports and failed to encourage domestic manufacturing. 

FDI for the Pharma sector in greenfield investments are channelled under the automatic route, and brownfield projects are placed under the government approval route. To regulate the drug manufacturing sector, the pharmaceutical industry was governed by strict norms. Since the medical devices industry was part of the Pharma sector, it was also bound by these norms which hampered its growth.

The medical devices industry felt that it was unfair to club medical devices with drugs as it resulted in operational challenges and delays. According to the revised position, the current FDI policy for the pharmaceutical sector which covers medical devices is amended to carve out medical device as a segment, to allow 100% FDI under the automatic route for both greenfield and brownfield investments in this segment. The change is expected to encourage investments from abroad which will give this industry the much required capital boost. As a result, it will allow the industry to focus on capacity building, product development, technology sharing and establish itself in India. In this era of specialisation, India has achieved a noteworthy position within the machine and drugs segments of the pharmaceutical market.  This new change will enable the medical devices industry to reach the status that the other segments of the Indian pharmaceutical industry have achieved.

The amendment will be effective from 21 January 2015.

 

SKP
19 Adi Marzban Path | Ballard Estate | Fort | Mumbai 400 001 | India   
+91 22 6730 9000 |
skpgrp.info@skpgroup.com | www.skpgroup.com

Mumbai | Pune | Hyderabad | New Delhi | Chennai  | Bengaluru

LinkedIn
Twitter
Facebook
Google Plus
ABOUT THIS BUSINESS ALERT
This SKP Business Alert contains general information existing at the time of its preparation only. It is intended as a news update and is not intended to be comprehensive nor to provide specific accounting, business, financial, investment, legal, tax or other professional advice or opinion or services. This business alert is not a substitute for such professional advice or services, and it should not be acted on or relied upon or used as a basis for any decision or action that may affect you or your business. Before making any decision or taking any action that may affect you or your business, you should consult a qualified professional adviser and also refer to the source pronouncement/documents on which this business alert is based. It is also expressly clarified that this business alert is not a solicitation or an invitation of any sort whatsoever or a source of advertising from SKP Group or any of its entities to create any adviser-client relationship.

Whilst every effort has been made to ensure the accuracy of the information contained in this business alert, this cannot be guaranteed, and neither SKP Group nor any related entity shall have any liability to any person or entity that relies on the information contained in this publication. Any such reliance is solely at the user's risk.


© 2014 SKP Group. All rights reserved.